Genmab A/S (NASDAQ:GMAB) Price Target Cut to $45.00 by Analysts at Truist Financial

Genmab A/S (NASDAQ:GMAB) had its target price dropped by equities research analysts at Truist Financial from $50.00 to $45.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price objective would suggest a potential upside of 123.51% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on GMAB. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a report on Thursday, February 13th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Finally, William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.33.

Genmab A/S Price Performance

Shares of NASDAQ GMAB traded down $1.85 during trading on Tuesday, reaching $20.13. 1,480,995 shares of the stock traded hands, compared to its average volume of 885,455. The stock has a market capitalization of $13.32 billion, a P/E ratio of 11.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88. The company has a 50-day moving average of $21.30 and a 200-day moving average of $22.59.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Deep Track Capital LP purchased a new stake in shares of Genmab A/S during the 4th quarter valued at $41,740,000. Brandywine Global Investment Management LLC purchased a new stake in Genmab A/S during the fourth quarter valued at about $33,804,000. Two Sigma Advisers LP lifted its stake in Genmab A/S by 168.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock worth $34,509,000 after purchasing an additional 1,038,400 shares during the last quarter. Two Sigma Investments LP lifted its position in Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after buying an additional 938,455 shares during the last quarter. Finally, Marshall Wace LLP grew its position in Genmab A/S by 162.2% during the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock valued at $23,422,000 after acquiring an additional 694,243 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.